Striatal dopamine D1 and D2 receptors in burning mouth syndrome

Pain. 2003 Jan;101(1-2):149-54. doi: 10.1016/s0304-3959(02)00323-8.

Abstract

Animal studies have indicated that the nigrostriatal dopaminergic system is involved in central pain modulation. In a recent positron emission tomography (PET) study, we demonstrated presynaptic dysfunction of the nigrostriatal dopaminergic pathway in burning mouth syndrome, which is a chronic pain state. The objective of the present study was to examine striatal dopamine D1 and D2 receptors in these patients. We used 11C-NNC 756 and 11C-raclopride to study D1 and D2 receptor binding in a PET study in ten burning mouth patients and 11 healthy controls. Patients underwent a structured psychiatric evaluation and an electrophysiological test for the excitability of the blink reflex. The striatal uptake of 11C-NNC 756 did not differ between patients and controls. In a voxel-level analysis, the uptake of 11C-raclopride was statistically significantly higher in the left putamen in burning mouth patients (corrected P-value 0.038 at cluster-level). In the region of interest analysis, the D1/D2 ratio was 7.7% lower in the right putamen (0.64+/-0.04 vs. 0.69+/-0.04, P=0.01) and 6.4 % lower in the left putamen (0.65+/-0.05 vs. 0.70+/-0.05, P=0.05) when compared to controls. Increased 11C-raclopride uptake and the subsequent decrease in the D1/D2 ratio may indicate a decline in endogenous dopamine levels in the putamen in burning mouth patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Benzazepines
  • Benzofurans
  • Burning Mouth Syndrome / diagnostic imaging*
  • Burning Mouth Syndrome / physiopathology*
  • Carbon Radioisotopes
  • Chronic Disease
  • Corpus Striatum / physiology*
  • Dopamine Antagonists
  • Humans
  • Middle Aged
  • Raclopride
  • Receptors, Dopamine D1 / physiology*
  • Receptors, Dopamine D2 / physiology*
  • Tomography, Emission-Computed

Substances

  • Benzazepines
  • Benzofurans
  • Carbon Radioisotopes
  • Dopamine Antagonists
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Raclopride
  • odapipam